UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
25
NOTIFICATION
OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File Number: 001-38064
COSCIENS
BIOPHARMA INC.
Nasdaq
Capital Market
(Exact
name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
c/o
Norton Rose Fulbright Canada, LLP
222
Bay Street, Suite 3000, PO Box 53
Toronto,
ON M5K 1E7
(Address,
including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
Common
Shares, no par value
(Description
of class of securities)
Please
place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ 17
CFR 240.12d2-2(a)(1)
☐ 17
CFR 240.12d2-2(a)(2)
☐ 17
CFR 240.12d2-2(a)(3)
☐ 17
CFR 240.12d2-2(a)(4)
☐ Pursuant
to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration
on the Exchange.1
☒ Pursuant
to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing
the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
1
Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Pursuant
to the requirements of the Securities Exchange Act of 1934, COSCIENS Biopharma Inc. certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned
duly authorized person.
| |
COSCIENS
Biopharma Inc. |
| |
|
|
| DATE:
August 26, 2025 |
By: |
/s/
Giuliano La Fratta |
| |
|
Giuliano
La Fratta |
| |
|
Chief
Financial Officer |
